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1. Introduction 
The new phenylalanine analogue, L-carboranyl- 
alanine (Car) [l] was recently found to be a good 
probe for investigating some special properties of the 
aromatic recognition site of chymotrypsin [2] . The 
icosahedral side chain of Car is somewhat larger than 
the phenyl ring of Phe, rotating about its 1,4 axis. 
Yet it is easily accomodated by chymotrypsin; the 
concomitant deformation of the recognition site 
propagated to the mechanistic site (especially Ser 195) 
is probably the reason that Car esters are not hydrol- 
ysed by the enzyme. 
One of the aims of our laboratory is to study 
hormone-receptor interactions. After the promising 
results with chymotrypsin as a model, we are investiga- 
ting the use of Car replacements of Phe, Tyr, and Trp 
in polypeptide hormones. 
Phenylalanine in position 4 seems to be quite 
important for enkephalin action, because a number 
of analogues with replacements of this amino acid 
by others all show reduced or even missing opiate 
receptor affinity and biological activity (review [3] ; 
see also [4-61). An introduction of Car into this 
position seemed ideally suitable to see whether or 
not carboranylalanine analogues of peptide hormones 
can be expected to have exceptional features. 
We have therefore prepared [4carboranylalanine, 
S-leucine] enkephalin, H.Tyr-Gly-Gly-Car-Leu.OH 
and investigated its ability to displace [3H]naloxone 
from rat brain opiate receptor preparations according 
to the technique developed in the laboratory of Snyder 
[7] . [S-Methionine] -enkephalin, [S-leucine] enke- 
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phalin, and N(a)-acetyl- [5-methionine] -enkephalin 
amide were synthesized for comparison. 
It was found that [Car4, Leu’] -enkephalin binds 
better than [Leu’] -enkephalin (about equally well as 
[Met’] -enkephalin) and that N(a)-acetyl-[Mets] - 
enkephalin amide is virtually inactive. The implications 
of these findings in terms of enkephalin-opiate 
receptor interaction are discussed. 
2. Materials and methods 
[4_Carboranylalanine, S-leucine] -enkephalin was 
synthesized by a classical procedure (to be published, 
Helv. Chim. Acta) via the following analytically pure 
intermediates: 
BocCar-Leu.OMe (m.p. 176’C; [o] g--38.1”, 
c 0.53 in methanol), 
Boc.Tyr--Gly-Gly-Car-Leu-OMe (crystals from 
chloroform/petroleum ether, m.p. 12%13O’C) and 
Boc+Tyr-Gly-Gly-Car-Leu.OH (m.p. 14O’C). 
The final product, HCl, H.Tyr-Gly-Gly-Car- 
Leu.OH, had m.p. 147°C (decomposition) and 
[a];-2.05” (c 0.44 in methanol). 
N(o)-Acetyl-[5-methionine] -enkephalin amide 
was synthesized in a similar manner (report for Helv. 
Chim, Acta, in preparation). Crystallized from ethyl 
acetate/ether as colorless platelets, m.p. 192’C, 
[o]$3.2’ (c 1 .O in methanol). 
Opiate receptor affinities were determined by a 
modified version of the binding assay described by 
Pasternak et al. [7]. Male Sprague-Dawley rats 
(250-300 g) of the Canadian Breeding Laboratories 
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were decapitated and after removal of the cerebellum 
the brains were homogenized in 30 vol ice-cold 
standard buffer (50 mM Tris-HCl, pH 7.7). The com- 
bined homogenates were centrifuged at 30 000 X g 
for 30 min at 4°C and the membranes reconstituted 
in the original volume of standard buffer. After incuba- 
tion at 37°C for 30 min and subsequent centrifugation 
the pellet was again suspended in the initial volume 
of fresh standard buffer to yield the final membrane 
suspension. Aliquots (2 ml) of the membrane prepara- 
tion were incubated for 1 h at 0°C [8] with 1 ml 
standard buffer containing the peptide to be tested 
and [3H]naloxone (17.7 Ci/mmol; New England 
Nuclear Corp.) at a final concentration of 0.5 nM. At 
the end of the incubation the reaction mixtures were 
filtered through Whatman GF/B filters under vacuum 
at 4°C; the filters were then washed with two 5 ml 
portions ice-cold standard buffer. Subsequently the 
filters were transferred to scintillation vials and 
treated with 1 ml Soluene (Packard) for 30 min, 
whereupon 0.5 ml acetic acid and 10 ml Aquasol (New 
England Nuclear Corp.) were added. After shaking 
for 30 min the vials were counted at an efficiency of 
40-45%. Stereospecific binding as determined by 
displacement of [3H]naloxone with excess (10 PM) 
cold [Met’] -enkephalin accounted for 60-70% of 
total binding. Values of half-maximal inhibition 
(IC50) of the stereospecific binding were obtained 
graphically from semi-logarithmic plots. Each com- 
pound was tested at least three times and [Met’] - 
enkephalin was included in each binding experiment 
for comparison. 
3. Results and discussion 
According to our experience with corticotropin 
and melanotropin derivatives, naloxone displacement 
[7] is possibly a more reliable indication for specific 
interaction of opioid agonists and antagonists with 
the opiate receptor than dihydromorphine displace- 
ment [9] . (A number of non-analgesic hormone 
derivatives were found to be active in the latter, but 
not in the former test: Peter Schiller and Alex Eberle, 
unpublished observations.) We therefore used the 
former assay system without as yet looking into the 
effects of sodium, potassium, manganese and calcium 
ions, which are supposed to differentiate between 
opioid agonists and antagonists [ 10,111. 
A typical experiment for the displacement of 
[3H]naloxone by [Mets] -enkephalin and [Car4,Leus]. 
enkephalin is plotted in fig.1. In table 1, the average 
values of half-maximal specific displacement (KS0 
[ 121) are expressed as molar affinities (1 /ICSO) in 
percent [MetS]enkephalin molar affinity. 
Fig.1. Displacement of [‘Hlnaloxone by [Met’] enkephalin (o-o) and [Car’, Leu5]enkephalin (a- - -A) from rat-brain 
opiate receptors. Naloxone concentration, 0.5 nM. Each point represents the mean of 3 measurements r SEM. Abscissa: molar 
concentration of the enkephalin peptides. Ordinate: percent naloxone bound. 
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Table 1 
Relative molar affinities of enkephalin analogs 
Analog % Receptor affinity relative 
to [Mets] enkephalin 
October 1917 
[Met5 ] enkephalin 
[Leu’] enkephalin 
H.Tyr-Gly-Gly-Car-LeuQH 
Ac.Tyr-Gly-Gly-Phe-Met.NH, 
1ooa 
38 * gb 
116 : lgb 
0.1 
aIC50 1.2 X lo-’ M in this assay system 
bMean of three determinations * SEM 
Whereas the affinity of [Leu’] enkephalin was 
found to be about l/3 of that of [Met’] -enkephalin, 
a result that is in good agreement with those of other 
authors [12,13], [Car“, Leu’] -enkephalin is approx. 
equally potent, but N(o)-acetyl-[Met’] -enkephalin 
amide only about l/1000. 
3 .l . The nature of the Phe4-recognizing site of the 
opiate receptor 
Obviously, the replacement of the aromatic phenyl 
ring of phenylalanine by the slightly bulkier, but 
more lipophilic, carboranyl system results in a tighter 
association of the peptide with the opiate receptor. 
The situation is quantitatively similar to that of the 
interaction of Z.Ala-Ala-Car.OH and Z.Ala-Ala- 
Phe.OH with chymotrypsin: the former is an approx. 
3 times better inhibitor (Ki 0.3 mM) than the latter 
(Ki 1 mM) [2] . It appears that the opiate receptor carries 
a phenyl recognition site comparable to the corresponding 
‘pocket’of chymotrypsin in that, like the enzyme,it is 
capable of accomodating the carboranyl icosahedron. 
Whether or not this accomodation is accompanied by a 
deformative adaptation of the recognition site and 
affects the ability of the receptor to be ‘triggered’by the 
enkephalin is presently under investigation. Despite 
the similarities, at least one difference between the 
two recognition sites remains: whereas tyrosine is 
about as easily adapted by chymotrypsin as are phenyl- 
alanine and tryptophan, the analogue, [Tyr4, Leu’] - 
enkephalin retains only about 3% of the dihydro- 
morphine displacing potency [6]. If this is true, the 
opiate receptor molecule, unlike chymotrypsin, must 
lack the possibility of adapting the p-hydroxyl group. 
3.2. The a-amino group of the enkephalins and the 
opiate receptor 
The very low level of activity found here for 
N(o)-acetyl-[Mets] -enkephalin amide agrees with the 
findings of Bradbury et al. [4] that a positive charge 
at the N-terminus is required for binding. The virtual 
inactivity of the compound is certainly not due to the 
C-terminal carboxyamide group, because [Met’] - 
enkephalin amide [4] and [D-Ala*, Met’] -enkephalin 
amide [5,14] belong to the most active compounds 
hitherto known. 
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